MedTrace Logo

Expanded Access Program of Venetoclax and Navitoclax for Pediatric Patients with Relapsed or Refractory ALL or LL

NCT05215405 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2025-02-03

No results posted yet for this study

Summary

The overall goal of this expanded access program is to provide Venetoclax and Navitoclax to patients with acute lymphocytic leukemia (ALL) or lymphoblastic lymphoma (LL) who have exhausted standard treatments.

Conditions

  • Relapsed Childhood ALL
  • Relapsed Childhood Lymphoblastic Lymphoma

Interventions

DRUG

Venetoclax

Venetoclax will be administered orally once daily (QD), continuously. Each dose of venetoclax should be taken with approximately 240 mL of water within 30 minutes after the completion of a meal, preferably breakfast. * Day 1 (200 mg equivalent): * Patients 20 \< 30 kg will take 70 mg * Patients 30 \< 35 kg will take120 mg * Patients 35 to 45 kg will take 200 mg * Day 2 onwards (400 mg equivalent): * Patients 20 \< 30 kg will take 170 mg * Patients 30 \< 35 kg will take 250 mg * Patients 35 to 45 kg will take 400 mg

DRUG

Navitoclax

Navitoclax will be administered orally once daily, starting on day 3 of cycle 1 and then may start on day 1 for subsequent cycles. Navitoclax should be taken at the same time each day approximately 24 hours apart. Dosing will be based on the recommended phase II dosing as per the phase I data and subsequent dose recommendations. * Patients 20 \< 45 kg will take 25 mg * Patients 45 kg or more will take 50 mg

Sponsors & Collaborators

  • Kathleen Ludwig

    lead OTHER

Eligibility

Min Age
4 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05215405 on ClinicalTrials.gov